Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.
Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.
The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.
The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.
In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.
Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.
A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.